A previous study on the effects of different muscarinic agonists on lung cancer proposed the activation of the EGFR/PI3K/AKT pathway due to M3 activation with partial participation of matrix metallopeptidases (MMPs), but the full mechanism is still unclear [32]. The gene discussed is EGFR; the disease is lung carcinoma.